- Home
- XBIO vs SPHL Comparison
XBIO vs SPHL Comparison
Compare XBIO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- SPHL
- Stock Information
- Founded
- XBIO N/A
- SPHL 2002
- Country
- XBIO United States
- SPHL Singapore
- Employees
- XBIO N/A
- SPHL N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- SPHL Homebuilding
- Sector
- XBIO Health Care
- SPHL Consumer Discretionary
- Exchange
- XBIO Nasdaq
- SPHL Nasdaq
- Market Cap
- XBIO 5.8M
- SPHL 5.7M
- IPO Year
- XBIO N/A
- SPHL 2024
- Fundamental
- Price
- XBIO $2.72
- SPHL $0.49
- Analyst Decision
- XBIO Hold
- SPHL
- Analyst Count
- XBIO 1
- SPHL 0
- Target Price
- XBIO N/A
- SPHL N/A
- AVG Volume (30 Days)
- XBIO 9.9K
- SPHL 493.3K
- Earning Date
- XBIO 05-08-2025
- SPHL 02-21-2025
- Dividend Yield
- XBIO N/A
- SPHL N/A
- EPS Growth
- XBIO N/A
- SPHL 413.11
- EPS
- XBIO N/A
- SPHL 0.09
- Revenue
- XBIO $2,500,284.00
- SPHL $11,020,429.00
- Revenue This Year
- XBIO $14.23
- SPHL N/A
- Revenue Next Year
- XBIO N/A
- SPHL N/A
- P/E Ratio
- XBIO N/A
- SPHL $5.34
- Revenue Growth
- XBIO N/A
- SPHL 112.84
- 52 Week Low
- XBIO $2.20
- SPHL $0.35
- 52 Week High
- XBIO $5.20
- SPHL $7.80
- Technical
- Relative Strength Index (RSI)
- XBIO 48.09
- SPHL N/A
- Support Level
- XBIO $2.32
- SPHL N/A
- Resistance Level
- XBIO $2.61
- SPHL N/A
- Average True Range (ATR)
- XBIO 0.15
- SPHL 0.00
- MACD
- XBIO 0.07
- SPHL 0.00
- Stochastic Oscillator
- XBIO 99.83
- SPHL 0.00
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.